(3S)-1-[6-(2-aminopyrazolo[1,5-a]pyrimidin-3-yl)pyrimidin-4-yl]-N,N-diethylpiperidine-3-carboxamide | 1202226-11-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (3S)-1-[6-(2-aminopyrazolo[1,5-a]pyrimidin-3-yl)pyrimidin-4-yl]-N,N-diethylpiperidine-3-carboxamide
• CAS: 1202226-11-6
• 化学式: C₂₀H₂₆N₈O
• 分子量: 394.479
• InChiKey: DKQKJWFBAJGEBC-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  、 二乙胺 在 水 、 sodium hydroxide 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 四氢呋喃 为溶剂， 生成 (3S)-1-[6-(2-aminopyrazolo[1,5-a]pyrimidin-3-yl)pyrimidin-4-yl]-N,N-diethylpiperidine-3-carboxamide
  参考文献：
  名称：

  2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2

  摘要：

  Constitutive activation of the EPO/JAK2 signaling cascade has recently been implicated in a variety of myeloproliferative disorders including polycythemia vera, essential thrombocythemia and myelofibrosis. In an effort to uncover therapeutic potential of blocking the EPO/JAK2 signaling cascade, we sought to discover selective inhibitors that block the kinase activity of JAK2. Herein, we describe the discovery and structure based optimization of a novel series of 2-amino-pyrazolo[1,5-a]pyrimidines that exhibit potent inhibition of JAK2. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.053

文献信息

• 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2
  作者：Mark W. Ledeboer、Albert C. Pierce、John P. Duffy、Huai Gao、David Messersmith、Francesco G. Salituro、Suganthini Nanthakumar、Jon Come、Harmon J. Zuccola、Lora Swenson、Dina Shlyakter、Sudipta Mahajan、Thomas Hoock、Bin Fan、Wan-Jung Tsai、Elaine Kolaczkowski、Scott Carrier、James K. Hogan、Richard Zessis、S. Pazhanisamy、Youssef L. Bennani

  DOI：10.1016/j.bmcl.2009.10.053

  日期：2009.12

  Constitutive activation of the EPO/JAK2 signaling cascade has recently been implicated in a variety of myeloproliferative disorders including polycythemia vera, essential thrombocythemia and myelofibrosis. In an effort to uncover therapeutic potential of blocking the EPO/JAK2 signaling cascade, we sought to discover selective inhibitors that block the kinase activity of JAK2. Herein, we describe the discovery and structure based optimization of a novel series of 2-amino-pyrazolo[1,5-a]pyrimidines that exhibit potent inhibition of JAK2. (C) 2009 Elsevier Ltd. All rights reserved.